FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Tim Heise

Research Profile

Chemicals & Drugs

Devices

Glucose Clamp Technique

Procedures

Disorders

Concepts & Ideas

Co-author Network

Publications

TOP 3
Leszek Nosek; K Roggen; M Kaiser; S Arnolds; C Gottschalk; Lutz Heinemann; Tim Heise
Insulin aspart has a shorter duration of action than human insulin over a wide dose-range.
Geremia B Bolli; Raphael Dahmen; Tanja Eisenblaetter; Annke D Hahn; Tim Heise; Ronald Schmidt; Reinhard H A Becker
Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes.
Tim Heise; Leszek Nosek; S G Bøttcher; H Hastrup; H Haahr
Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Tim Heise (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Leszek Nosek; K Roggen; M Kaiser; S Arnolds; C Gottschalk; Lutz Heinemann; Tim Heise
Insulin aspart has a shorter duration of action than human insulin over a wide dose-range.
Diabetes, obesity & metabolism 2013;15(1):77-83.
2012: Geremia B Bolli; Raphael Dahmen; Tanja Eisenblaetter; Annke D Hahn; Tim Heise; Ronald Schmidt; Reinhard H A Becker
Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes.
Diabetes care 2012;35(12):2626-30.
2012: Tim Heise; Leszek Nosek; S G Bøttcher; H Hastrup; H Haahr
Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes.
Diabetes, obesity & metabolism 2012;14(10):944-50.
2012: Tim Heise; L Hermanski; Leszek Nosek; S Rasmussen; A Feldman; H Haahr
Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.
Diabetes, obesity & metabolism 2012;14(9):859-64.
2012: Lutz Heinemann; Tim Heise; A Krasner; Leszek Nosek; P Pichotta; K Albus; F Flacke; S Steiner
U-100, pH-Neutral formulation of VIAject(®) : faster onset of action than insulin lispro in patients with type 1 diabetes.
Diabetes, obesity & metabolism 2012;14(3):222-7.
2012: Alexander Strom; Lutz Heinemann; Tim Heise; Christian Herder; Wolfgang Koenig; Hubert Kolb; Stephan Martin; Michael Roden; Nanette C Schloot; Marie-Christine Simon
Improved preservation of residual beta cell function by atorvastatin in patients with recent onset type 1 diabetes and high CRP levels (DIATOR trial).
PloS one 2012;7(3):e33108.
2011: Christoph Kapitza; Milan Zdravkovic; Eric Zijlstra; Stine Segel; Tim Heise; Anne Flint
Effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide.
Journal of clinical pharmacology 2011;51(6):951-5.
2011: Thomas Jax; Tim Heise; Leszek Nosek; Jennifer Gable; Gene Lim; Christopher Calentine
Automated near-continuous glucose monitoring measured in plasma using mid-infrared spectroscopy.
Journal of diabetes science and technology 2011;5(2):345-52.
2010: S Arnolds; Klaus Rave; U Hövelmann; A Fischer; C Sert-Langeron; Tim Heise
Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2010;118(9):662-4.
2007: Sabine Arnolds; Tim Heise
Inhaled insulin.
Best practice & research. Clinical endocrinology & metabolism 2007;21(4):555-71.
2007: Klaus Rave; Kerstin Roggen; Sibylle Dellweg; Tim Heise; Heike tom Dieck
Improvement of insulin resistance after diet with a whole-grain based dietary product: results of a randomized, controlled cross-over study in obese subjects with elevated fasting blood glucose.
The British journal of nutrition 2007;98(5):929-36.
2007: Tim Heise; T R Pieber
Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies.
Diabetes, obesity & metabolism 2007;9(5):648-59.
2007: Tim Heise; Leszek Nosek; H Spitzer; Lutz Heinemann; E Niemöller; Annke D Frick; Reinhard H A Becker
Insulin glulisine: a faster onset of action compared with insulin lispro.
Diabetes, obesity & metabolism 2007;9(5):746-53.
2007: Klaus Rave; Tim Heise; Andreas Pfützner; Anders H Boss
Coverage of postprandial blood glucose excursions with inhaled technosphere insulin in comparison to subcutaneously injected regular human insulin in subjects with type 2 diabetes.
Diabetes care 2007;30(9):2307-8.
2007: O Klein; J Lynge; Lars A Endahl; B Damholt; Leszek Nosek; Tim Heise
Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
Diabetes, obesity & metabolism 2007;9(3):290-9.
2007: Tim Heise
Clinical therapeutics. Realising the value of modern insulins: reaching further with rapid-acting insulin analogues. XIX World Diabetes Congress, Cape Town, South Africa, December 3, 2006. Forward.
Clinical therapeutics 2007;29 Suppl D():S133-4.
2007: Tim Heise
Getting closer to physiologic insulin secretion.
Clinical therapeutics 2007;29 Suppl D():S161-5.
2006: M Hausmann; S Dellweg; C Osborn; Lutz Heinemann; A Buchwald; R Rosskamp; P Genova; Tim Heise
Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof-of-concept study.
Diabetes, obesity & metabolism 2006;8(5):574-80.
2006: Marcus Hompesch; B Troupin; Tim Heise; B Elbroend; Lars A Endahl; H Haahr; Lutz Heinemann
Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups.
Diabetes, obesity & metabolism 2006;8(5):568-73.
2006: Klaus Rave; Leszek Nosek; John Posner; Tim Heise; Kerstin Roggen; Ewoud-Jan van Hoogdalem
Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes--results of a hyperglycaemic glucose clamp study.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2006;21(8):2166-71.
2006: Thomas Kaiser; Tim Heise; Leszek Nosek; Uta Eckers; Peter T Sawicki
Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients.
Journal of hypertension 2006;24(7):1397-403.
2006: Susanne Bott; Corinna Tusek; L V Jacobsen; Lars A Endahl; Eberhard Draeger; Christoph Kapitza; Tim Heise
Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes.
Diabetic medicine : a journal of the British Diabetic Association 2006;23(5):522-8.
2005: Susanne Bott; Corinna Tusek; Lutz Heinemann; H H Friberg; Tim Heise
The pharmacokinetic and pharmacodynamic properties of biphasic insulin Aspart 70 (BIAsp 70) are significantly different from those of biphasic insulin Aspart 30 (BIAsp 30).
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2005;113(9):545-50.
2005: Tim Heise; Susanne Bott; Corinna Tusek; Jens-Armin Stephan; Tom Kawabata; Deborah Finco-Kent; Cameron Liu; Alan Krasner
The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a prospective randomized pharmacodynamic study.
Diabetes care 2005;28(9):2161-9.
2005: Thomas Danne; Reinhard H A Becker; Tim Heise; Claudia Bittner; Annke D Frick; Klaus Rave
Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes.
Diabetes care 2005;28(9):2100-5.
2005: Klaus Rave; Sabine Flesch; W Nikolaus Kühn-Velten; Beate C Hompesch; Lutz Heinemann; Tim Heise
Enhancement of blood glucose lowering effect of a sulfonylurea when coadministered with an ACE inhibitor: results of a glucose-clamp study.
Diabetes/metabolism research and reviews 2005;21(5):459-64.
2005: Susanne Bott; Y A Shafagoj; P T Sawicki; Tim Heise
Impact of smoking on the metabolic action of subcutaneous regular insulin in type 2 diabetic patients.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2005;37(7):445-9.
2005: Klaus Rave; Susanne Bott; Lutz Heinemann; Sue Sha; Reinhard H A Becker; Susan A Willavize; Tim Heise
Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin.
Diabetes care 2005;28(5):1077-82.
2004: Tim Heise; Lutz Heinemann; Simon Heller; Christian Weyer; Yan Wang; Susan Strobel; Orville G Kolterman; David G Maggs
Effect of pramlintide on symptom, catecholamine, and glucagon responses to hypoglycemia in healthy subjects.
Metabolism: clinical and experimental 2004;53(9):1227-32.
2004: Christoph Kapitza; Marcus Hompesch; Birgitte Scharling; Tim Heise
Intrasubject variability of inhaled insulin in type 1 diabetes: a comparison with subcutaneous insulin.
Diabetes technology & therapeutics 2004;6(4):466-72.
2004: Tim Heise; Leszek Nosek; Birgitte Biilmann Rønn; Lars A Endahl; Lutz Heinemann; Christoph Kapitza; Eberhard Draeger
Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.
Diabetes 2004;53(6):1614-20.
2004: Christoph Kapitza; Klaus Rave; K Ostrowski; Tim Heise; Lutz Heinemann
Reduced postprandial glycaemic excursion with biphasic insulin Aspart 30 injected immediately before a meal.
Diabetic medicine : a journal of the British Diabetic Association 2004;21(5):500-1.
2004: Christoph Kapitza; Tim Heise; Robert S Fishman; David A Shapiro; Vidhya Gopalakrishnan; Klaus Rave; Susanne Bott; Ayesh D Perera; Lutz Heinemann
Impact of particle size and aerosolization time on the metabolic effect of an inhaled insulin aerosol.
Diabetes technology & therapeutics 2004;6(2):119-27.
2003: Tim Heise; Theodor Koschinsky; Lutz Heinemann; Volker Lodwig
Hypoglycemia warning signal and glucose sensors: requirements and concepts.
Diabetes technology & therapeutics 2003;5(4):563-71.
2002: Ayesh D Perera; Christoph Kapitza; Leszek Nosek; Robert S Fishman; David A Shapiro; Tim Heise; Lutz Heinemann
Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes.
Diabetes care 2002;25(12):2276-81.
2002: Tim Heise; Susanne Bott; Klaus Rave; A Dressler; R Rosskamp; Lutz Heinemann
No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes.
Diabetic medicine : a journal of the British Diabetic Association 2002;19(6):490-5.
2001: Klaus Rave; Tim Heise; Andreas Pfützner; Lutz Heinemann; Peter T Sawicki
Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients.
Diabetes care 2001;24(5):886-90.
2000: Lutz Heinemann; W Klappoth; Klaus Rave; Beate C Hompesch; R Linkeschowa; Tim Heise
Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer.
Diabetes care 2000;23(9):1343-7.
2000: Tim Heise; K Magnusson; B Gröbel; Lutz Heinemann; Klaus Rave; R Bender; Peter T Sawicki
A cross-over evaluation of different methods and devices to measure blood pressure in type 1 diabetic patients with nephropathy.
Blood pressure monitoring 2000;5(3):175-80.
2000: Lutz Heinemann; R Linkeschova; Klaus Rave; Beate C Hompesch; M Sedlak; Tim Heise
Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo.
Diabetes care 2000;23(5):644-9.
2000: Lutz Heinemann; U Krämer; H M Klötzer; M Hein; D Volz; M Hermann; Tim Heise; Klaus Rave
Noninvasive glucose measurement by monitoring of scattering coefficient during oral glucose tolerance tests. Non-Invasive Task Force.
Diabetes technology & therapeutics 2000;2(2):211-20.
1999: Tim Heise; Lutz Heinemann; K Kristahn; M Berger; Peter T Sawicki
Insulin sensitivity in patients with essential hypertension: no influence of the ACE inhibitor enalapril.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 1999;31(7):418-23.
1999: Klaus Rave; R Bender; Tim Heise; Peter T Sawicki
Value of blood pressure self-monitoring as a predictor of progression of diabetic nephropathy.
Journal of hypertension 1999;17(5):597-601.
1999: Klaus Rave; Lutz Heinemann; L Puhl; U Gudat; James R Woodworth; C Weyer; Tim Heise
Premixed formulations of insulin lispro. Activity profiles in type 1 diabetic patients.
Diabetes care 1999;22(5):865-6.
1999: Lutz Heinemann; K Sinha; C Weyer; M Loftager; S Hirschberger; Tim Heise
Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304.
Diabetic medicine : a journal of the British Diabetic Association 1999;16(4):332-8.
1999: Klaus Rave; Tim Heise; P Clausson; S Hirschberger; Lutz Heinemann
Lack of effects of the beta3-adrenoreceptor agonist UL-TG 307 on insulin sensitivity and insulin secretion in Type 2 diabetic patients.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 1999;107(7):442-6.
1999: Klaus Rave; Tim Heise; C Weyer; Peter T Sawicki; Lutz Heinemann
Measurement of insulin sensitivity: influence of potassium supply during euglycaemic glucose clamps in healthy volunteers.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 1999;107(5):313-7.
1999: Renate Kimmerle; Lutz Heinemann; Tim Heise; R Bender; C Weyer; S Hirschberger; M Berger
Influence of continuous combined estradiol-norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women.
Menopause (New York, N.Y.) 1999;6(1):36-42.
1998: J Meinhold; Tim Heise; Klaus Rave; Lutz Heinemann
Electrocardiographic changes during insulin-induced hypoglycemia in healthy subjects.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 1998;30(11):694-7.
1998: C Weyer; R Linkeschowa; Tim Heise; H T Giesen; M Spraul
Implications of the traditional and the new ACSM physical activity recommendations on weight reduction in dietary treated obese subjects.
International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 1998;22(11):1071-8.
1998: Lutz Heinemann; C Weyer; M Rauhaus; S Heinrichs; Tim Heise
Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart.
Diabetes care 1998;21(11):1910-4.
1998: Tim Heise; Lutz Heinemann; Achim Starke
Simulated postaggression metabolism in healthy subjects: metabolic changes and insulin resistance.
Metabolism: clinical and experimental 1998;47(10):1263-8.
1998: Klaus Rave; Tim Heise; C Weyer; J Herrnberger; R Bender; S Hirschberger; Lutz Heinemann
Intramuscular versus subcutaneous injection of soluble and lispro insulin: comparison of metabolic effects in healthy subjects.
Diabetic medicine : a journal of the British Diabetic Association 1998;15(9):747-51.
1998: Tim Heise; K Magnusson; Lutz Heinemann; Peter T Sawicki
Insulin resistance and the effect of insulin on blood pressure in essential hypertension.
Hypertension 1998;32(2):243-8.
1998: Tim Heise; C Weyer; A Serwas; S Heinrichs; J Osinga; P Roach; James R Woodworth; U Gudat; Lutz Heinemann
Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin.
Diabetes care 1998;21(5):800-3.
1998: Tim Heise; M Berger; Peter T Sawicki
Non-evidence-based concepts are still established in the treatment of IDDM.
Hormone research 1998;50 Suppl 1():74-8.
1997: C Weyer; Tim Heise; Lutz Heinemann
Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture.
Diabetes care 1997;20(10):1612-4.
1997: Lutz Heinemann; C Weyer; Klaus Rave; O Stiefelhagen; M Rauhaus; Tim Heise
Comparison of the time-action profiles of U40- and U100-regular human insulin and the rapid-acting insulin analogue B28 Asp.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 1997;105(3):140-4.
1997: Lutz Heinemann; T Traut; Tim Heise
Time-action profile of inhaled insulin.
Diabetic medicine : a journal of the British Diabetic Association 1997;14(1):63-72.
1996: Lutz Heinemann; C Kapitza; Achim Starke; Tim Heise
Time-action profile of the insulin analogue B28Asp.
Diabetic medicine : a journal of the British Diabetic Association 1996;13(7):683-4.
1996: Lutz Heinemann; Tim Heise; L C Wahl; M E Trautmann; J Ampudia; Achim Starke; Mathias Berger
Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin.
Diabetic medicine : a journal of the British Diabetic Association 1996;13(7):625-9.
1995: Lutz Heinemann; Tim Heise; A Klepper; J Ampudia; R Bender; Achim Starke
Time-action profiles of the intermediate-acting insulin analogue des(64,65)-human proinsulin.
Diabète & métabolisme 1995;21(6):415-9.
1995: Lutz Heinemann; Tim Heise; J Ampudia; Peter T Sawicki; G Sindelka; G Brunner; Achim Starke
Four week administration of an ACE inhibitor and a cardioselective beta-blocker in healthy volunteers: no influence on insulin sensitivity.
European journal of clinical investigation 1995;25(8):595-600.
1994: F J Ampudia-Blasco; Lutz Heinemann; R Bender; A Schmidt; Tim Heise; Mathias Berger; Achim Starke
Comparative dose-related time-action profiles of glibenclamide and a new non-sulphonylurea drug, AG-EE 623 ZW, during euglycaemic clamp in healthy subjects.
Diabetologia 1994;37(7):703-7.
1993: Lutz Heinemann; Tim Heise; L N Jorgensen; Achim Starke
Action profile of the rapid acting insulin analogue: human insulin B28Asp.
Diabetic medicine : a journal of the British Diabetic Association 1993;10(6):535-9.
1993: Lutz Heinemann; Tim Heise; K Kamper
Biotrans: description of a data transfer program for the biostator.
The International journal of artificial organs 1993;16(4):213-7.